霉酚酸酯与环磷酰胺治疗重症IgA肾病的临床对照  被引量:5

Mycophenolate mofetil therapy versus cyclophosphamide treatment in patients with sever IgA nephropathy

在线阅读下载全文

作  者:苏清涛 

机构地区:[1]泸溪县人民医院,湖南泸溪416100

出  处:《中国民族民间医药》2009年第9期101-103,共3页Chinese Journal of Ethnomedicine and Ethnopharmacy

摘  要:目的:比较霉酚酸脂(MMF)与环磷酰胺(CTX)静滴治疗重症IgA肾病的临床疗效。方法:29例IgA肾病患者分别采用激素联合MMF治疗(MMF组,n=15),或采用激素联合CTX静注治疗(CTX组,n=14)。MMF剂量为1.5g/d,诱导疗程均≥6个月;CTX剂量为0.4g,隔日1次静脉滴注,总量≤8g。两组患者基础病情无差异,随访时间≥12个月,疗效指标包括临床缓解率、24h尿蛋白定量和血脂变化。观察两组的临床疗效和副作用。结果:①临床缓解率:治疗12个月时,MMF组临床,总有效率高于CTX组,分别为81%和57%(P<0.05);②MMF组24h尿蛋白明显低于CTX组(0.6±0.3和1.4±0.8,P<0.05);③MMF组血脂明显降低(P<0.05)。而CTX组无变化;④MMF组副作用的发生率明显低于CTX组(13%和43%,P<0.05)。结论:激素联合MMF治疗重症IgA肾病,临床缓解率高于CTX静脉滴注疗法,能更有效降低蛋白尿,改善血脂水平,且副作用发生率低于CTX疗法。To compare the clinical efficacy of mycophenolate mofetil (MMF) with that of cyclophosphamide (CTX) in the treatment of sever IgA nephropathy.Methods:Forty-one patients with sever IgA nephropathy were enrolled into this study and were divided into MMF and CTX groups. MMF group included 15 cases that were treated with MMF at a dosage of 1.5 g/d. CTX group enrolled 14 cases that were given intravenous drip 0.4 g/2d and the total dosage was less than 8g. These patients were followed up for more than 12 months. The clinical efficacy and side effects were compared between the two groups.Resuhs:①Clinical remission rate in the 12th month was 81% in MMF therapy and it was 57%in CTX group. The difference of the clinical remission rate between the two groups was significant (P〈0.05) .②The concentration of proteinuria in 24h in MMF group was lower than that in CTX group (P〈0.05) .③After the therapy, the level of blood-lipid decreased obviously in MMF group, but it did not changed in CTX group (P〈 0.05) .④The side effect in both groups were 13% ( MMF group) vs 43% (CTX group) (P〈0.05) .Conclusion:The combination therapy of MMF and steroid was more effective than CTX intravenous drip in treatment of sever lgA nephropathy and with fewer side effects.

关 键 词:IGA肾病 霉酚酸脂 环磷酰胺 治疗 

分 类 号:R692[医药卫生—泌尿科学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象